Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Degardin M, Oliveira J, Geoffrois L, Rolland F, Armand JP, Bastit P, Chauvergne J, Fargeot P, van Glabbeke M, Lentz MA, Tresca P, Boudillet J, Fumoleau P, Cappelaere P. Degardin M, et al. Among authors: lentz ma. Ann Oncol. 1998 Oct;9(10):1103-7. doi: 10.1023/a:1008446706578. Ann Oncol. 1998. PMID: 9834823 Free article. Clinical Trial.
Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.
Cappelaere P, Guiochet N, Chauvergne J, Bastit P, Armand JP, Lentz MA, Van Glabbeke M, Herait P, Fumoleau P. Cappelaere P, et al. Among authors: lentz ma. Eur J Cancer. 1992;28(2-3):484-5. doi: 10.1016/s0959-8049(05)80083-8. Eur J Cancer. 1992. PMID: 1591069 Clinical Trial. No abstract available.
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Lhommé C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, Van Glabbeke M, Matthieu-Boué A, Mignard D, Chevallier B. Lhommé C, et al. Among authors: lentz ma. J Clin Oncol. 1999 Oct;17(10):3136-42. doi: 10.1200/JCO.1999.17.10.3136. J Clin Oncol. 1999. PMID: 10506610 Clinical Trial.
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M. Chevallier B, et al. Among authors: lentz ma. J Clin Oncol. 1995 Feb;13(2):314-22. doi: 10.1200/JCO.1995.13.2.314. J Clin Oncol. 1995. PMID: 7844592 Clinical Trial.
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
Manegold C, Drings P, Pawinski A, Lentz MA, van Glabbeke M, van Zandwijk N, Bachmann P, Schnaars Y, Skacel Z, Zatloukal P, Dolensky J, Jackevicius A, Petruzelka L, Giaccone G. Manegold C, et al. Among authors: lentz ma. Ann Oncol. 1996 Aug;7(6):637-9. doi: 10.1093/oxfordjournals.annonc.a010683. Ann Oncol. 1996. PMID: 8879380 Free article. Clinical Trial.
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P. Dieras V, et al. Among authors: lentz ma. Br J Cancer. 1996 Aug;74(4):650-6. doi: 10.1038/bjc.1996.416. Br J Cancer. 1996. PMID: 8761385 Free PMC article. Clinical Trial.
36 results